Newsletter Subscription

Enter Name and Email

12 June 2014 - Adrian to chair session and present at neuroscience webinar

Adrian Newman-Tancredi will be chairing a session at an online neuroscience conference taking place from 17th to 19th June 2014. The webinar, organized by the online life-science conference organizer, TargetMeeting, will provide wide-ranging and free access to international speakers without the need to travel (the only requirements are a headphone and an internet connection). 

As part of the session (see program below), Adrian will give a presentation outlining novel strategies for treatment of motor side effects in Parkinson's disease (PD). PD affects over 1% of the population over the age of 60 and constitutes a social and economic burden. The main therapeutic treatment for PD is to compensate for deficient dopamine levels in the brain by administering the dopamine precursor, L-DOPA. Although initially effective in attenuating the trembling and rigidity that characterise the motor symptoms of PD, L-DOPA causes troubling side effects (notably jerky, uncontrolled movements known as dyskinesia) upon prolonged administration. There are currently no approved treatments for this but novel serotonergic drugs offer the hope to alleviate the discomfort of PD patients suffering from such side-effects.The webinar will describe the striking data obtained recently in animals models of PD in a project funded by the Michael J. Fox Foundation and supervised by Adrian Newman-Tancredi as Principal Investigator in his role as Chief Scientific Officer of Neurolixis.

Adrian has extensive experience of neuropsychiatric drug discovery and has presented to a wide variety of audiences. If you would like more information: Contact.

Tuesday, 17th June 2014, Session 1: Cellular & Molecular Neuroscience-I,

09h00 – 10h30 AM, EST (New York) = 15h00 - 16h30 CET (Europe).

Session Chair: Dr. Adrian Newman-Tancredi

For full details and free access to abstracts click here.


9h00 – 9h30 AM
"CT-guided blocks and neuroablation of the ganglion impar (Walther) in perineal pain: anatomy, technique, safety, and efficacy."
Kamayni Agarwal, Therapiezentrum für Integrative Palliativmedizin und Schmerztherapie, Elbe Kliniken Stade - Buxtehude GmbH, Stade, Germany.


9h30 – 10h00 AM
"Targeting serotonin 5-HT1A receptors for treatment of L-DOPA-induced dyskinesia in Parkinson’s disease: new hope from highly selective full agonists."
Adrian Newman-Tancredi PhD, DSc, Chief Scientific Officer, Neurolixis Inc., France.


10h00 – 10h30 AM
"Novel approches in investigating the complex physiological phenomena by modulation of intracellular pH dynamics."
Juliana Knocikova, Centre National de la Recherche Scientifique (CNRS), Université de Nice – Sophia Antipolis, Nice, France.